BioRestorative Therapies Inc Cash Flow Conversion Efficiency
BioRestorative Therapies Inc cash flow conversion efficiency. Based on the latest financial reports, BioRestorative Therapies Inc (BRTX) has a cash flow conversion efficiency ratio of -1.259x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.81 Million) by net assets ($3.03 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of BioRestorative Therapies Inc (2010–2025)
Cash flow conversion efficiency of BioRestorative Therapies Inc from 2010 to 2025. This chart illustrates how BioRestorative Therapies Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View BioRestorative Therapies Inc stock quote for real-time trading data and today's change.
BioRestorative Therapies Inc Cash Flow Conversion Ratio Explained
BioRestorative Therapies Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
BioRestorative Therapies Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioRestorative Therapies Inc ranked by their cash flow conversion efficiency. Also see BioRestorative Therapies Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Logismos Information Systems S.A
AT:LOGISMOS
|
0.026x |
|
Trencor
JSE:TRE
|
0.000x |
|
Eifelhöhen-Klinik AG
F:EIF
|
-0.003x |
|
TG-17, Inc. Common Stock
NASDAQ:OBAI
|
0.293x |
|
Green River Holding Co Ltd
TWO:8444
|
-0.174x |
|
Poxel SA
PA:POXEL
|
-0.124x |
|
Electronic City Indonesia Tbk
JK:ECII
|
-0.015x |
|
Tonkens Agrar AG
XETRA:GTK
|
-0.032x |
Annual Cash Flow Conversion Efficiency for BioRestorative Therapies Inc (2010–2025)
The table below shows the annual cash flow conversion efficiency of BioRestorative Therapies Inc from 2010 to 2025. Review BioRestorative Therapies Inc free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $356.74K | $-10.79 Million | -30.243x | -3034.91% |
| 2024-12-31 | $8.53 Million | $-8.23 Million | -0.965x | -50.09% |
| 2023-12-31 | $10.00 Million | $-6.43 Million | -0.643x | -11.85% |
| 2022-12-31 | $10.29 Million | $-5.91 Million | -0.575x | -272.69% |
| 2021-12-31 | $21.60 Million | $-3.33 Million | -0.154x | -110.45% |
| 2020-12-31 | $-1.33 Million | $-1.96 Million | 1.475x | +172.42% |
| 2019-12-31 | $-12.78 Million | $-6.92 Million | 0.542x | -8.33% |
| 2018-12-31 | $-8.64 Million | $-5.10 Million | 0.591x | +4.80% |
| 2017-12-31 | $-6.84 Million | $-3.85 Million | 0.564x | -43.66% |
| 2016-12-31 | $-5.00 Million | $-5.00 Million | 1.000x | +25.25% |
| 2015-12-31 | $-3.91 Million | $-3.12 Million | 0.799x | +70.47% |
| 2014-12-31 | $-6.89 Million | $-3.23 Million | 0.469x | +17.22% |
| 2013-12-31 | $-6.69 Million | $-2.67 Million | 0.400x | -35.45% |
| 2012-12-31 | $-5.14 Million | $-3.18 Million | 0.619x | -18.78% |
| 2011-12-31 | $-3.69 Million | $-2.81 Million | 0.762x | -22.18% |
| 2010-12-31 | $-744.22K | $-729.22K | 0.980x | -- |
About BioRestorative Therapies Inc
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected fro… Read more